Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

GlaxoSmithKline launches hunt for new chief executive

Drug group is said to have kicked off succession planning, but it is in no rush to replace Witty
GlaxoSmithKline launches hunt for new chief executive
Chief executive Andrew Witty is not expected to leave until next year at the earliest

British drug giant GlaxoSmithKline (LON:GSK) is launching a hunt for a new chief executive to succeed Andrew Witty, it emerged on Monday.

Chairman Philip Hampton is said to have told shareholders that the company's board will prioritise succession planning in the next couple of years, although Witty is not expected to go until next year at the earliest.

Hampton is in no rush and is keen to ensure a considered and orderly transition, Reuters cited unidentified sources as saying. Witty himself is said to be set to play a role in finding his successor.

There has been speculation about takeover interest in Glaxo and some shareholders have called on the company to consider breaking itself up.

Witty, who has faced criticism from some about Glaxo's relatively lacklustre share price, has insisted Glaxo is better off intact than splitting itself into its constituent parts, such as pharmaceuticals and consumer health.

He told a news conference earlier this month: “When you look at the uncertainty of the general global environment, I actually think having a more balanced set of businesses is exactly the right course for us.”

Shares in Glaxo rose 3p to 1413.5p in early London trading.

 

Phil-Waller.jpg


Register here to be notified of future GSK Company articles
View full GSK profile

GlaxoSmithKline plc Timeline

Related Articles

shutterstock_234586750.jpg
October 24 2016
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.
picture of cells under microscope
November 30 2016
Vaxil is testing Immucin in combination with other immunotherapy modalities
blood_56ceb82789b61.jpg
February 25 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.